Go Pro

Pale Fire Capital SE Buys Shares of 153,505 Cybin Inc. $HELP

Cybin logo with Healthcare background
Image from MarketBeat Media, LLC.

Key Points

  • Pale Fire Capital SE initiated a Cybin position by purchasing 153,505 shares valued at approximately $1.015 million, representing about 0.21% of the company. Institutional investors collectively own 17.94% of Cybin.
  • Cybin shares rose 3.0% to $11.95, with the stock trading well above its 50-day and 200-day moving averages. The company reported a quarterly loss of $0.91 per share, missing the $0.80 analyst consensus.
  • Analyst sentiment remains positive, with a consensus “Buy” rating and an average price target of $48.60; recent targets include $62 from TD Cowen and $16 from Wells Fargo.
  • MarketBeat previews top five stocks to own in October.

Pale Fire Capital SE purchased a new position in shares of Cybin Inc. (NASDAQ:HELP - Free Report) in the 2nd quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 153,505 shares of the company's stock, valued at approximately $1,015,000. Pale Fire Capital SE owned approximately 0.21% of Cybin as of its most recent filing with the Securities and Exchange Commission (SEC).

Several other institutional investors and hedge funds have also made changes to their positions in the stock. Osaic Holdings Inc. boosted its stake in shares of Cybin by 46.7% during the second quarter. Osaic Holdings Inc. now owns 7,543 shares of the company's stock valued at $63,000 after acquiring an additional 2,400 shares during the last quarter. Bank of America Corp DE raised its stake in Cybin by 66.8% in the 2nd quarter. Bank of America Corp DE now owns 29,443 shares of the company's stock valued at $247,000 after purchasing an additional 11,790 shares during the last quarter. Finally, Millennium Management LLC lifted its holdings in Cybin by 1,388.5% in the 4th quarter. Millennium Management LLC now owns 1,028,549 shares of the company's stock valued at $8,414,000 after purchasing an additional 959,448 shares in the last quarter. 17.94% of the stock is currently owned by hedge funds and other institutional investors.

Cybin Trading Up 3.0%

Shares of NASDAQ:HELP opened at $11.95 on Thursday. The firm has a market cap of $873.07 million, a price-to-earnings ratio of -3.96 and a beta of 0.63. The stock's 50-day moving average price is $9.10 and its two-hundred day moving average price is $6.60. Cybin Inc. has a 12-month low of $3.76 and a 12-month high of $14.35.

Cybin (NASDAQ:HELP - Get Free Report) last posted its quarterly earnings data on Friday, August 14th. The company reported ($0.91) EPS for the quarter, missing analysts' consensus estimates of ($0.80) by ($0.11). As a group, research analysts forecast that Cybin Inc. will post -2.95 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of brokerages have recently commented on HELP. TD Cowen lifted their price target on shares of Cybin from $8.00 to $62.00 and gave the stock a "buy" rating in a report on Thursday, August 20th. Wall Street Zen upgraded shares of Cybin from a "strong sell" rating to a "sell" rating in a research report on Saturday, August 29th. Finally, Wells Fargo & Company assumed coverage on shares of Cybin in a research note on Monday, July 27th. They issued an "overweight" rating and a $16.00 target price for the company. Five investment analysts have rated the stock with a Buy rating, According to data from MarketBeat.com, the stock presently has a consensus rating of "Buy" and a consensus price target of $48.60.

Read Our Latest Stock Analysis on Cybin

About Cybin

(Free Report)

Cybin Inc is a clinical-stage biopharmaceutical company focused on the development of psychedelic-based therapeutics for the treatment of mental health disorders. Headquartered in Toronto and listed on the NASDAQ under the symbol HELP, Cybin pursues research and development programs intended to harness the therapeutic potential of psychedelic compounds to address conditions with significant unmet need.

The company operates a drug discovery and development platform aimed at creating novel small-molecule psychedelic analogs and tailored formulations.

See Also

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat
Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Should You Invest $1,000 in Cybin Right Now?

Before you consider Cybin, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Cybin wasn't on the list.

While Cybin currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

The 10 Best High-Yield Dividend Stocks for 2026 Cover

Discover the 10 Best High-Yield Dividend Stocks for 2026 and secure reliable income in uncertain markets. Download the report now to identify top dividend payers and avoid common yield traps.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines